Clinical trials: Blood-Borne Infections
mHealth, PMTCT
Mobile Strategies for Women's and Children's Health: Optimizing Adherence and Efficacy of PMTCT/ART
The investigators are conducting a 3-arm randomized trial comparing the effects of unidirectional SMS (ie: "push" messaging to participant) vs. bidirectional SMS dialogue between participant and provider vs.
- Conditions
- mHealth, PMTCT, Adherence, Medication, SMS
- Trial name
- Mobile WAChx (NCT02400671)
- Testing
- SMS messaging
- Where
- 6 sites in Kenya
- Volunteers
- 825 people, healthy volunteers welcome
- Sponsor
- University of Washington
HIV-1, Human Immunodeficiency Virus 1
MK-8510 Monotherapy for the Treatment of Anti-retroviral naïve Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8510-002)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and anti-retroviral activity of MK-8510 monotherapy in anti-retroviral-naïve HIV-1 infected participants.
- Conditions
- HIV-1, Human Immunodeficiency Virus 1, Immunodeficiency Virus Type 1, Human, Human Immunodeficiency Virus Type 1
- Trial name
- NCT05700734
- Testing
- MK-8510
- Sponsor
- Merck Sharp & Dohme LLC
HIV 1 Infection, HIV 2 Infection
A Study to Evaluate Performance, Usability, and Contrived Result Interpretation of TruPlex HIV/HepB/Syphilis Rapid Test
The objectives of this study are as follows: To evaluate the clinical performance of the TruPlex test using capillary blood, EDTA whole blood, EDTA plasma, and SST serum samples collected by trained operators in point-of-care…
- Conditions
- HIV 1 Infection, HIV 2 Infection, Syphilis Infection, Hepatitis B Infection
- Trial name
- NCT07563309
- Testing
- TruPlex HIV/HepB/Syphilis Rapid Test
- Where
- 3 sites in South Africa
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- bioLytical Laboratories
Smoking Cessation, Smoking
Smoking Cessation Pilot for People Living With HIV (PLWH)
The overall goal of this pilot study is to evaluate the feasibility of the Lumme smartphone app for smoking cessation in people living with HIV (PLWH) and evaluate its effect on smoking cessation.
- Conditions
- Smoking Cessation, Smoking, Smoking Behaviors, Smoking Reduction
- Trial name
- NCT04808609
- Testing
- Lumme mobile phone application, Standard of Care
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Columbia University
Hepatitis C Patients
Immune Dysregulation in Hepatitis C Patients With or Without Arthritis
The purpose of this study is to study the role of the Immune System in causing arthritis in patients with Hepatitis C.
- Trial name
- NCT01195987
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- The Center for Rheumatic Disease, Allergy, & Immunology
HIV Infection
A Trial to Determine the Long-term Durability of Virologic Suppression in Kaletra Recipients With Imperfect Adherence
This study will enroll completers of a prior 24 week MEMS cap study of Kaletra adherence, conducted in 2005 - 2006, and repeat the MEMS monitoring for an additional 24 weeks in 2008/2009 on the current antiretroviral anchor drug.
- Trial name
- NCT00785616
- Testing
- MEMS cap monitoring
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Montefiore Medical Center
HIV Infections
The Safety of Zidovudine Plus Interferon-Alpha in HIV-Infected Children
PRIMARY: To determine the maximum tolerated dose of interferon-alfa (IFN-A) alone and in combination with zidovudine (AZT); to assess the safety and tolerance of IFN-A alone and in combination with AZT.
- Trial name
- NCT00000967
- Testing
- Interferon alfa-2a, Zidovudine
- Where
- 9 sites in United States, Puerto Rico
- Volunteers
- 52 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis B
Follow-up Study 16-20 Years After Primary Vaccination Against Hepatitis B of Newborns From HBeAg+ & HBsAg+ Mothers
The purpose of this study is to evaluate the persistence of anti-hepatitis B surface antigen (anti-HBs) antibodies 16, 17, 18, 19 and 20 years after administration of the first dose of the study vaccine.
- Trial name
- NCT00240500
- Testing
- Engerix™-B
- Where
- Thailand
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Liver Cancer, Hepatitis B
Viral & Host Factors Associated With Hepatitis B Virus-related Hepatocellular Carcinoma
Adult liver cancer is the third leading cause of cancer deaths worldwide. The major risk factor for liver cancer is hepatitis B virus (HBV) infection.
- Conditions
- Liver Cancer, Hepatitis B, Hepatitis C, Hepatobiliary Cancers Liver
- Trial name
- NCT00767936
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- Stanford University
Hepatitis C, Chronic
Directly Observed Therapy for HCV in Chennai, India
The primary objective of this pilot trial is to evaluate the feasibility of 12 weeks vs. 24 weeks of field-based directly observed therapy (DOT) for HCV therapy in a resource-limited setting.
- Trial name
- C-DOT (NCT02541409)
- Testing
- Sofosbuvir, Pegylated Interferon alfa-2a, Ribavirin
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
HIV Infections
Safety and Immune Response Study of the Vaccine ALVAC vCP1452 Alone or in Combination With AIDSVAX B/B
The purpose of this study is to see if the vaccines tested are safe when given alone and when given together, and how the immune system responds to the vaccines.
- Trial name
- NCT00007332
- Testing
- ALVAC(2)120(B,MN)GNP (vCP1452), MN rgp120/HIV-1 and GNE8 rgp120/HIV-1
- Where
- 17 sites in United States
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV/AIDS
ADELANTE: A Randomized Controlled Trial to Improve Engagement in Care for Latinos With HIV
The goal of this study is to test the effectiveness of ADELANTE on viral suppression among Latinos with HIV and viral non-suppression.
- Trial name
- NCT06274632
- Testing
- ADELANTE
- Where
- 2 sites in United States
- Volunteers
- 250 people
- Sponsor
- Massachusetts General Hospital
HIV Infections
A Double-Blind, Randomized Parallel Group Study Comparing Procysteine to Placebo in HIV-Infected Patients Who Are Taking Antiretroviral Nucleosides
To compare the efficacy and safety of orally administered Procysteine with placebo in HIV-infected patients who are receiving 1 of the following: (1) zidovudine (AZT) alone; (2) didanosine (ddI) alone; (3) AZT plus ddI; or (4)…
- Trial name
- NCT00002114
- Testing
- Procysteine
- Volunteers
- 125 people
- Sponsor
- Free Radical Sciences
Chronic Hepatitis C
Safety and Effect of Elbasvir/Grazoprevir Combination Therapy in Hemodialysis Patients With Chronic Hepatitis C
The number of hemodialysis patients with chronic renal failure in Japan exceeds 0.3 million and is showing an increasing trend. The rate of infection with hepatitis C virus (HCV) is high in hemodialysis patients, and it has been…
- Trial name
- NCT03022006
- Testing
- elbasvir, grazoprevir
- Where
- Japan
- Volunteers
- 60 people
- Sponsor
- Norte Study Group
HIV Infections
Multicenter Trial of Immunologic Markers to Predict Long Term Virologic Outcomes
Purpose is to identify whether immune markerscan predict success of salvage anti-retroviral therapy.
- Trial name
- NCT00440206
- Where
- 5 sites in Canada
- Volunteers
- 50 people
- Sponsor
- Ottawa Hospital Research Institute
Human Immunodeficiency Virus
Problems With Immune Recovery in the Gut Tissue
The aim of this study is to find out if the process of HIV replication in the lymph tissue and gut tissue of people taking HIV drugs causes long-term damage to the ability of the gut to protect you from other infections and…
- Trial name
- NCT01460433
- Testing
- Genital and rectal swabbing
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Hepatitis C Virus (HCV)
Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World Data
The objective of this study is to assess the safety, tolerability and effectiveness of 8-week Glecaprevir/Pibrentasvir (G/P) in participants taking either prescribed or illicit drugs.
- Trial name
- NCT07419347
- Where
- 2 sites in Canada
- Volunteers
- 2,000 people
- Sponsor
- AbbVie
Viral Hepatitis B, Viral Hepatitis C
Therapeutic Option for Hepatitis B and C: a French Cohort
The cohort will integrate clinical, genetic, pharmacogenomics, environmental, biomarkers and behavioral data in a large number of patients and will be a leading equipment for crossdisciplinary and translational research on…
- Trial name
- HEPATHER (NCT01953458)
- Where
- France
- Volunteers
- 20,902 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Hiv, Transgenderism
Drug-Drug Interaction Study in Trans Women Living With HIV
Introduction: Transgender (trans) women have been found to be at higher risk of and to be disproportionally affected by HIV. Trans women with HIV have also been found to have low usage and adherence rates to antiretroviral…
- Trial name
- T-DDI (NCT05663892)
- Testing
- Biktarvy 50/200/25 Tab, Estradiol Tablets
- Where
- Canada
- Volunteers
- 45 people
- Sponsor
- Maple Leaf Research
HIV Infections
Pharmacokinetics of Low Dose Raltegravir
The purpose of this study is to study and compare the pharmacokinetics profile of low dose raltegravir (RAL) (400mg OD and 800mg OD) and standard dose of 400mg BID in Thai HIV-infected patients.
- Trial name
- NCT01159132
- Testing
- raltegravir
- Where
- Thailand
- Volunteers
- 24 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.